The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials.

IF 2.8 3区医学 Q2 PHARMACOLOGY & PHARMACY

BMC Pharmacology & Toxicology Pub Date : 2024-02-23 DOI:10.1186/s40360-024-00740-y

Seyyed Mostafa Arabi, Mostafa Shahraki-Jazinaki, Mahla Chambari, Leila Sadat Bahrami, Sara Sabeti, Mohammaed Ibrahim Mohaildeen Gubari, Basil D Roufogalis, Amirhossein Sahebkar

{"title":"The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials.","authors":"Seyyed Mostafa Arabi, Mostafa Shahraki-Jazinaki, Mahla Chambari, Leila Sadat Bahrami, Sara Sabeti, Mohammaed Ibrahim Mohaildeen Gubari, Basil D Roufogalis, Amirhossein Sahebkar","doi":"10.1186/s40360-024-00740-y","DOIUrl":null,"url":null,"abstract":"Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature.Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I2.Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I2 = 66.3% and P = 0.01).Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885610/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-024-00740-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previous studies investigating the effect of oral supplementation of paricalcitol on reactive protein levels in chronic kidney disease (CKD) patients reported inconsistent findings. In this systematic review and meta-analysis, we have analyzed and interpreted the results obtained from previous randomized clinical trials on the effect of paricalcitol on C-reactive protein in CKD patients in the literature.

Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases were searched until January 2023 and related articles were obtained through a careful screening process allowing extraction of required data from selected articles. The effect size was calculated using a random effect model and weighted mean differences (WMD) and 95% confidence intervals (CI). Heterogeneity among studies was evaluated using Cochran's Q test and I².

Results: Amongst the 182 articles obtained from the initial search, 4 studies (6 arms) were finally included in the meta-analysis. Pooled analysis shows that C-reactive protein levels significantly decrease after oral supplementation with paricalcitol (WMD: -2.55 mg/L, 95% CI (-4.99 to -0.11; P = 0.04). The studies used in this meta-analysis showed significant heterogeneity (I² = 66.3% and P = 0.01).

Conclusion: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.

查看原文本刊更多论文

口服帕立骨化醇对慢性肾病患者 C 反应蛋白水平的影响：对随机对照试验数据进行GRADE评估的系统综述和剂量反应荟萃分析。

背景：以往关于口服帕立骨化醇对慢性肾脏病（CKD）患者反应蛋白水平影响的研究报告结果并不一致。在本系统综述和荟萃分析中，我们分析并解读了以往文献中关于帕立骨化醇对 CKD 患者 C 反应蛋白影响的随机临床试验结果：方法：检索了MEDLINE、SciVerse Scopus和Clarivate Analytics Web of Science数据库，检索期至2023年1月，通过仔细筛选获得相关文章，并从所选文章中提取所需数据。采用随机效应模型、加权平均差（WMD）和 95% 置信区间（CI）计算效应大小。使用 Cochran's Q 检验和 I2 评估了研究之间的异质性：在初步搜索获得的 182 篇文章中，最终有 4 项研究（6 个研究臂）被纳入荟萃分析。汇总分析显示，口服帕立骨化醇后，C反应蛋白水平明显下降（WMD：-2.55 mg/L，95% CI（-4.99 至 -0.11；P = 0.04）。本荟萃分析中使用的研究显示出显著的异质性（I2 = 66.3%，P = 0.01）：结论：CKD 患者口服帕立骨化醇可显著降低 C 反应蛋白水平，从而预防 CKD 的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY

CiteScore

4.80

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.

文献相关原料

公司名称	产品信息	采购帮参考价格